Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical firm specializing in treatments for kidney and cardiovascular diseases, will have its CEO, Mike Raab, participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 3:00 p.m. ET. The event can be accessed through Ardelyx's Events and Presentations page, with a replay available for 60 days post-event. Ardelyx is advancing tenapanor, aimed at controlling serum phosphorus in CKD dialysis patients, with an NDA under FDA review and a PDUFA date set for April 29, 2021.

FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the 10^th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. ET on Wednesday, Feb. 24, 2021.

To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 60 days following the presentation.

About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA^® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-301229549.html

SOURCE Ardelyx

FAQ

When is Ardelyx's presentation at the SVB Leerink Global Healthcare Conference?

Ardelyx's presentation is scheduled for February 24, 2021, at 3:00 p.m. ET.

Who will represent Ardelyx at the healthcare conference?

Mike Raab, the president and CEO of Ardelyx, will represent the company.

How can I access Ardelyx's presentation from the SVB Leerink conference?

You can access the webcast of Ardelyx's presentation on their Events and Presentations page.

What is the PDUFA date for Ardelyx's NDA submission for tenapanor?

The PDUFA date for tenapanor's NDA is April 29, 2021.

What are the focus areas of Ardelyx's research and development?

Ardelyx focuses on innovative medicines for kidney and cardiovascular diseases, including treatments for high potassium levels and serum phosphorus control.